Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Serina Therapeutics (formerly AgeX) filed an 8-K on 9/9/25 for disclosures and financials.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on September 9, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is located in Huntsville, Alabama.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and disclosures, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing appears to be a standard corporate disclosure and does not contain information suggesting immediate or significant risk.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- September 9, 2025 (date) — Date of report
- Huntsville, Alabama (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
What was Serina Therapeutics, Inc. formerly known as?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.
When did the company change its name from AgeX Therapeutics, Inc.?
The company changed its name from AgeX Therapeutics, Inc. on June 6, 2017.
Where are Serina Therapeutics, Inc.'s principal executive offices located?
Serina Therapeutics, Inc.'s principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What is the SEC file number for Serina Therapeutics, Inc.?
The SEC file number for Serina Therapeutics, Inc. is 001-38519.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-09-09 15:23:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
Filing Documents
- ser-20250909.htm (8-K) — 25KB
- ser-20250908_ex991converti.htm (EX-99.1) — 19KB
- image_0.jpg (GRAPHIC) — 0KB
- 0001708599-25-000108.txt ( ) — 247KB
- ser-20250909.xsd (EX-101.SCH) — 2KB
- ser-20250909_lab.xml (EX-101.LAB) — 53KB
- ser-20250909_pre.xml (EX-101.PRE) — 31KB
- ser-20250909_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure Attached hereto as Exhibit 99.1 is a press release dated September 9, 2025 , for Serina Therapeutics, Inc. (the "Company"). The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that, the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated Sep t ember 9 , 2025, issued by Serina Therapeutics, Inc . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: September 9, 2025 By: /s/ Steve Ledger Chief Executive Officer